Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Profit After Tax (2019 - 2025)

Historic Profit After Tax for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$976000.0.

  • Cyclerion Therapeutics' Profit After Tax fell 3499.31% to -$976000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year increase of 5914.16%. This contributed to the annual value of -$3.1 million for FY2024, which is 7572.46% up from last year.
  • As of Q3 2025, Cyclerion Therapeutics' Profit After Tax stood at -$976000.0, which was down 3499.31% from -$324000.0 recorded in Q2 2025.
  • Cyclerion Therapeutics' Profit After Tax's 5-year high stood at $44.1 million during Q4 2022, with a 5-year trough of -$16.2 million in Q2 2021.
  • In the last 5 years, Cyclerion Therapeutics' Profit After Tax had a median value of -$1.8 million in 2023 and averaged -$2.9 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first skyrocketed by 50928.07% in 2022, then tumbled by 10955.59% in 2024.
  • Over the past 5 years, Cyclerion Therapeutics' Profit After Tax (Quarter) stood at -$10.8 million in 2021, then skyrocketed by 509.28% to $44.1 million in 2022, then crashed by 104.07% to -$1.8 million in 2023, then skyrocketed by 129.53% to $530000.0 in 2024, then tumbled by 284.15% to -$976000.0 in 2025.
  • Its last three reported values are -$976000.0 in Q3 2025, -$324000.0 for Q2 2025, and -$1.4 million during Q1 2025.